Related Experiment Video
Updated: Apr 29, 2026
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Use of covered Cheatham-Platinum stents in congenital heart disease
Ward Y Vanagt1, Björn Cools2, Derize E Boshoff2
1Department of Congenital and Pediatric Cardiology, University Hospital Gasthuisberg, Leuven, Belgium; Department of Pediatrics, Cardiovascular Research Institute Maastricht CARIM, Maastricht University Medical Center MUMC, Maastricht, The Netherlands; Department of Physiology, Cardiovascular Research Institute Maastricht CARIM, Maastricht University Medical Center MUMC, Maastricht, The Netherlands.
Insights
Covered Cheatham-Platinum (CCP) stents are safe and effective for congenital heart disease (CHD) interventions. These stents facilitate vessel sealing and dilation, improving outcomes in complex pediatric and adult cardiac cases.
Area of Science:
- Cardiology
- Interventional Cardiology
- Congenital Heart Disease
Background:
- The use of covered stents in congenital heart disease (CHD) remains a subject of debate.
- Covered Cheatham-Platinum (CCP) stents offer potential solutions for complex CHD interventions.
Purpose of the Study:
- To evaluate the feasibility and safety of using CCP stents in patients with CHD.
- To assess the outcomes of CCP stent application across various CHD conditions.
Main Methods:
- A single-center retrospective study analyzed CCP stent usage from 2003 to 2012.
- Patients were categorized into three groups: aortic coarctation (CoA), right ventricular outflow tract (RVOT) pre-stenting, and miscellaneous conditions.
- Data included patient demographics, stent characteristics, and procedural outcomes.
Main Results:
- 114 CCP stents were implanted in 105 patients (age range: 4.2-71.2 years).
- In CoA, CCP stents increased coarctation diameter (6mm to 15mm) and were used prophylactically in 51/54 cases.
- In RVOT, CCP stents successfully redilated stenotic grafts from 13mm to 22mm; diverse applications were noted in the miscellaneous group.
Conclusions:
- CCP stents can be safely deployed in patients with CHD.
- The stent's covering provides effective sealing of tears, enhancing safety and enabling more complete dilation.
- CCP stents represent a valuable tool for managing complex congenital and acquired heart defects.
Background:
Controversy remains regarding the use of covered stents in congenital heart disease (CHD). We evaluate the possibilities and safety of covered Cheatham-Platinum (CCP) stents in CHD.
Methods:
Single-center retrospective CHD-database study of all CCP stents, 2003-2012. Three study groups: aortic coarctation (CoA), right ventricular outflow tract pre-stenting for percutaneous revalvulation (RVOT), and miscellaneous. Continuous data expressed as median (range).
Results:
114 CCP stents in 105 patients, age 16.8 years (4.2-71.2). CoA group: 54 CCP stents in 51 patients: 3/54 for aneurysm exclusion, in 51/54 covering used "prophylactically" because of increased risk for vessel tear. Overall, CCP stenting increased the coarctation diameter from 6mm (0-15) to 15 mm (10-20) (p<0.001). RVOT group: 39 CCP stents in 37 patients (34 with RVOT graft, 3 with transannular patch): the graft lumen had shrunken from nominal 21 mm (10-26) to 13 mm (5-22); with the CCP stent the RVOT was redilated to 22 mm (16-26, p<0.001 vs stenosis). Miscellaneous group: 21 CCP stents in 17 patients: closure of Fontan-circuit fenestration (n=5), restoration of superior caval vein (n=2) or pulmonary artery (n=3) patency, relief of supra-pulmonary stenosis (n=2), exclusion of aberrant pulmonary arteries (n=1), cavopulmonary conduit expansion (n=2), Blalock-Taussig shunt flow reduction (n=1), and defibrillator lead protection from sharp stents (n=1). Hybrid procedures performed in 3/17 patients. CCP stent was used as rescue treatment in 2/patients to seal iatrogenic bleeding.
Conclusion:
CCP stents can safely be applied in CHD patients. The covering allows adequate sealing of existing or expected tears, thereby increasing the safety margin with more complete dilation.
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:24Cardiac Catheterization III: Left Heart Catheterization